Sun Pharma

Sun Pharma receives US FDA approval for BromSite

First NSAID approved for prevention of ocular pain in patients undergoing cataract surgery

Orchid Pharma, DLF among 10 stocks that remained in focus in Monday’s trade

Orchid Pharma shares closed 11.10 per cent up at Rs 43.05 after the company received an Establishment inspection report (EIR) from the US health regulator based on the successful inspection closure for the API manufacturing f

Orchid Pharma, DLF among 10 stocks that remained in focus in Monday’s trade

Sun Pharmaceutical shares gain on entering Japanese prescription market

According to the agreements entered into between the parties, a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of $293

Sun Pharmaceutical shares gain on entering Japanese prescription market

Sun Pharma enters Japanese prescription market

Acquires 14 prescription brands Sun Pharma has acquired 14 established prescription brands from Novartis in Japan. According to the agreements entered into between the parties, a wholly-owned subsidiary of Sun Pharma will acq

Sun Pharma partners with AstraZeneca India over Type II diabetes medicine

Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name 'Oxra'

Neutral rating on Sun Pharma: Q3FY16 driven by Taro

Strong performance of Taro was the key contributor during the quarter. Higher other income and lower tax rate resulted in PAT being 4% higher than our estimates.

Sun Pharma Q3 net profit surges threefold to Rs 1,417 cr

The drug major had posted a net profit of Rs 395.33 crore during the same period of previous fiscal.

Sun Pharma Q3 net profit surges threefold to Rs 1,417 cr

Sun Pharmaceutical gains on launching Imatinib Mesylate Tablets in US

Sun Pharmaceutical shares gained over 2 per cent on Wednesday after the company and its subsidiaries launched Imatinib Mesylate Tablets (therapeutic equivalent to Gleevec for indications approved by the FDA) in US market.

Sun Pharmaceutical gains on launching Imatinib Mesylate Tablets in US

M-cap of top 10 cos jumps by over Rs 1 lakh crore, Sun Pharma leads

The combined market valuation of top 10 most valued Indian companies advanced by a whopping Rs 1,02,667 crore last week, with Sun Pharma and TCS winning big amid a recovery in the broader market.

M-cap of top 10 cos jumps by over Rs 1 lakh crore, Sun Pharma leads

Top seven companies lose Rs 51,647 cr in m-cap

RIL, Infosys, HDFC Bank, ITC, CIL, ONGC and HUL were the laggards, while TCS, Sun Pharma and HDFC notched up gains in their m-cap.

Top seven companies lose Rs 51,647 cr in m-cap

Sun Pharma gets CCI nod to sell two CNS divisions to Strides

The company has received an order under the Competition Act, 2002, from the Competition Commission of India (CCI) approving the proposed transaction, Sun Pharmaceutical Industries said in a regulatory filing.

Sun Pharma gets CCI nod to sell two CNS divisions to Strides

WL dims Sun’s shine … a bit

A new year brings with it new hope but all indications are that 2016 is going to be a mixed bag for the pharmaceutical industry

A(sian Paints) to Zee Entertainment, six toppers

Six stocks — Asian Paints, Kotak Mahindra Bank, Hindustan Unilever, Lupin, Sun Pharma and Zee Entertainment — have consistently outperformed the benchmark Nifty in each of the last five years.

A(sian Paints) to Zee Entertainment, six toppers

Leaking ceilings, procedural lapses at Sun Pharma’s Halol plant: USFDA

Factory ceilings which leaked and failure to follow written procedures designed to prevent microbiological contamination of drugs are some of the major norm violations found by the USFDA at Sun Pharma's Halol plant.

Leaking ceilings, procedural lapses at Sun Pharma’s Halol plant: USFDA
Advertisement
Income Tax Calculator, Budget 2019, How to Calculate Income Tax

 

Stock Market

Advertisement
Advertisement

TRENDING NOW

BUDGET 2019

Related Articles